Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,533 | 17,169 | 18,116 | 19,464 | 19,126 |
| Other current assets | 74 | 138 | 182 | 250 | 59 |
| TOTAL | $18,607 | $17,307 | $18,298 | $19,714 | $19,185 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $18,607 | $17,307 | $18,298 | $19,714 | $19,185 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,054 | 6,034 | 5,460 | 5,206 | 6,569 |
| Accrued Expenses | 840 | 282 | 310 | 486 | 415 |
| TOTAL | $8,894 | $6,316 | $5,770 | $5,692 | $6,984 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,894 | $6,316 | $5,770 | $5,692 | $6,984 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 23,392 | 19,321 | 18,653 | 18,356 | 17,769 |
| Retained earnings | -73,245 | -66,997 | -62,844 | -58,416 | -54,245 |
| TOTAL | $9,713 | $10,991 | $12,528 | $14,022 | $12,201 |
| Total Liabilities And Equity | $18,607 | $17,307 | $18,298 | $19,714 | $19,185 |